2023 cohort company Nanowear gets FDA clearance for AI-enabled software that allows its wearable undergarment to estimate blood pressure. Learn more here.
2022 cohort company iCardio.ai announced a strategic partnership with UltraLinQ, a major PACS (Picture Archiving and Communication Systems) software provider. The partnership combines iCardio.ai's cutting-edge automated AI tools with UltraLinQ's robust image viewer and advanced reporting platform. Learn more here.
2023 cohort company Nanowear announced that its nanotechnology-enabled wearable and software platform, SimpleSenseTM, has received FDA 510(k) clearance for a novel AI-enabled Software-as-a-Medical Device (SaMD). Learn more here.
2022 cohort company Acorai received investment from CerraCap Ventures, a leading venture capital firm in healthcare innovation. The investment will boost the development and deployment of Acorai's novel Acorai Heart Monitor (AHM), which aims to solve critical challenges in heart failure management. Learn more here.
2022 cohort company Acorai secured more than $4.5m in funding to finance its clinical studies and move towards regulatory approval. The round was led by Solardis Health Ventures, with participation from KHP Ventures, Carma Fund and other US investors. Significant follow-on investment was taken from existing investors from across Sweden and the EU. Learn more here.
2023 cohort company MindMics was granted a patent for its cardiovascular monitoring via infrasound technology in everyday headphones. This patent marks a significant leap in the field of cardiovascular health, offering a novel, non-invasive approach to disease monitoring and management. Learn more here.
2021 cohort company SoniVie announced enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation. SoniVie is developing the only platform denervation technology with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and total lung denervation for chronic obstructive pulmonary disease with chronic bronchitis. Learn more here.
2020 cohort company Zeto achieves HITRUST risk-based, 2-year certification demonstrating the highest level of information protection assurance. Learn more here.
2023 cohort company SmartCardia has announced an exciting partnership with Kokilaben Dhirubhai Ambani Hospital (KDAH), Mumbai to revolutionize patient care for individuals with cardiac arrhythmia, a condition when the heartbeat is irregular due to a problem with the heart’s electrical signals. Learn more here.
